Dyadic International, Inc. (DYAI)
| Market Cap | 29.44M -5.9% |
| Revenue (ttm) | 3.81M +7.1% |
| Net Income | -7.29M |
| EPS | -0.21 |
| Shares Out | 36.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 811,501 |
| Open | 0.7300 |
| Previous Close | 0.7100 |
| Day's Range | 0.6951 - 0.8300 |
| 52-Week Range | 0.6546 - 1.3460 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+642.57%) |
| Earnings Date | May 13, 2026 |
About DYAI
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research a... [Read more]
Financial Performance
In 2025, Dyadic International's revenue was $3.09 million, a decrease of -11.59% compared to the previous year's $3.50 million. Losses were -$7.36 million, 26.8% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price target is $6.0.
News
Dyadic International Transcript: Lytham Partners Spring 2026 Investor Conference
Transitioning to a commercial stage, the company has launched six products in the past year and established global distribution and key partnerships, driving early revenues across life sciences, food, and bioindustrial markets. Recurring revenues and further launches are expected in 2026.
Dyadic International, Scripps Research team to evaluate Hantavirus vaccine
Dyadic International (DYAI) announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantavirus...
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology company fo...
Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology com...
Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET
Company invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ Company invites individual...
Dyadic International Transcript: Sidoti Micro-Cap Virtual Conference
The company has transitioned to a product-driven model, commercializing six animal-free protein products across life sciences, food nutrition, and bioindustrial markets. Strategic partnerships, scalable platforms, and a diversified revenue model support rapid growth, with recurring revenues expected to accelerate as products move from pilot to commercial scale.
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
JUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology com...
Dyadic International Slides: Investor presentation
Dyadic International has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Dyadic International Earnings Call Transcript: Q1 2026
Revenue grew 182% year-over-year to $1.1 million, driven by product launches and expanded partnerships. Loss from operations improved, and cash runway extends into Q2 2027. Commercial momentum is building across life sciences, food, and industrial segments.
Dyadic International Earnings release: Q1 2026
Dyadic International released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Dyadic International Quarterly report: Q1 2026
Dyadic International has published its Q1 2026 quarterly earnings report on May 13, 2026.
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biol...
Dyadic International Proxy statement: Proxy filing
Dyadic International filed a proxy statement on May 12, 2026, providing details for shareholder voting and corporate governance matters.
Dyadic International Slides
Dyadic International has posted slides in relation to its latest quarterly earnings report, which was published on May 1, 2026.
Dyadic International Proxy statement: Proxy filing
Dyadic International filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology co...
Dyadic International Earnings Call Transcript: Q4 2025
Transitioned to a commercial-stage biotech with new product launches and expanded partnerships, though 2025 revenue declined to $3.09M and net loss widened. Expecting revenue growth in 2026, with cash runway into 2027 and a focus on recurring revenue streams.
Dyadic International Earnings release: Q4 2025
Dyadic International released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
Dyadic International Annual report: Q4 2025
Dyadic International has published its Q4 2025 annual report on March 25, 2026.
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product sales E...
Dyadic International enter distribution partnership with IBT Bioservices
Dyadic Applied BioSolutions entered into an original equipment manufacturer distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices. Through this collaboration, Dyadic-produ...
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-enginee...
Dyadic International Transcript: Life Sciences Virtual Investor Forum
Transitioning from R&D to commercial operations, the company has launched multiple products in life sciences, food, and bioindustrial markets, leveraging its C1 and Dapibus platforms. Strategic partnerships and direct sales are driving early revenues, with significant growth expected from late 2026 as more products and collaborations mature.
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology co...
Dyadic International, Fermbox Bio launch of RNase-Free
Dyadic Applied BioSolutions and Fermbox Bio announced the commercial launch of animal-origin-free Recombinant DNase I. This represents the first commercialized product under the companies expanded col...